A month after filing a new drug application for Treanda in chronic lymphocytic leukemia, Cephalon Inc. said the drug met its endpoint in a pivotal trial in indolent non-Hodgkin's lymphoma patients who are refractory to rituximab. (BioWorld Today)

Paion AG gave its beleaguered investors a little autumnal cheer by raising hopes that its clot-busting stroke drug Desmoteplase might return to the clinic, despite a Phase III clinical trial miss earlier this year that precipitated a share price plunge. (BioWorld International)